Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation (NYSE: EW) generates frequent news as a structural heart medical device company focused on therapies for complex valve disease and structural heart failure. Company announcements highlight developments across transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical heart valve technologies, as well as clinical data, regulatory milestones and corporate updates.
News coverage often features clinical trial readouts and registry data for key Edwards platforms, including the SAPIEN TAVR valves, the SAPIEN M3 mitral valve replacement system, and the EVOQUE tricuspid valve replacement system. Releases describe long‑term outcomes from the PARTNER trial series, pivotal ENCIRCLE TMVR results, and real‑world EVOQUE registry findings, with a focus on safety, durability, regurgitation reduction and quality‑of‑life improvements for patients with limited treatment options.
Investors and clinicians can also follow regulatory and guideline‑related updates, such as U.S. Food and Drug Administration approvals for new transcatheter therapies, European CE Mark decisions, and evolving professional society guidelines for aortic, mitral and tricuspid disease management. Corporate news includes earnings releases, financial guidance, share repurchase announcements, participation in major healthcare conferences and leadership transitions disclosed through press releases and 8‑K filings.
In addition, Edwards Lifesciences reports on collaborations and initiatives in the broader cardiovascular ecosystem, such as its founding sponsorship of the American Heart Association’s Heart Valve Initiative. For readers tracking EW news, this mix of clinical, regulatory, financial and partnership updates provides insight into how the company is advancing structural heart therapies and executing its strategy over time.
Edwards Lifesciences (NYSE: EW) reported two-year TRISCEND II results presented at ACC.26 showing sustained benefits with the EVOQUE transcatheter tricuspid valve replacement system. Data showed near elimination of tricuspid regurgitation, improved health status and quality of life, no added device-related risk, and lower all-cause mortality when accounting for patient crossover.
Company noted prior 18-month ESC data and real-world evidence from >1,000 patients in the STS/ACC TVT Registry; EVOQUE is approved in the US and Europe.
Edwards Lifesciences (NYSE: EW) reaffirmed its structural heart leadership and expanded its global health initiative Every Heartbeat Matters, aiming to help 2 million more patients by the end of 2030. The program focuses on increasing diagnosis and treatment access for underserved structural heart patients, especially in low- and middle-income countries. Since 2014, the initiative and partners have impacted more than 4 million patients. The company emphasized innovation, partnerships, and the Edwards Lifesciences Foundation as vehicles to reduce financial, systemic, and geographic barriers to care.
Edwards Lifesciences (NYSE: EW) announced that CFO Scott Ullem will present at two investor conferences in March 2026: Barclays on March 10, 2026 at 10:00 a.m. ET and Leerink on March 11, 2026 at 10:00 a.m. ET.
Live webcasts of both presentations will be available on the company investor relations website, with archived recordings posted later the same day.
Edwards Lifesciences (NYSE: EW) will present at Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026. CFO Scott Ullem is scheduled to present at 10:15 a.m. ET. A live webcast and same‑day archived replay will be available on the company investor relations website.
Investors can access the webcast at the Edwards investor relations site for the presentation and later replay.
Edwards Lifesciences (NYSE: EW) reported Q4 2025 sales of $1.57B (up 13.3%) and Q4 TAVR sales of $1.16B (up 12.0%). FY2025 sales rose 11.5% with full-year TAVR sales of $4.5B. Q4 adjusted EPS was $0.58. The company raised confidence in FY2026 guidance: constant-currency revenue +8–10% and adjusted EPS $2.90–3.05, with TMTT expected to grow 35–45% to $740–780M.
Cash was ~$3.0B and total debt ~$600M. Management cited trial data, guideline updates, new approvals, and product launches as catalysts for 2026 growth.
Edwards Lifesciences (NYSE: EW) will report operating results for the quarter ended December 31, 2025 after market close on Tuesday, February 10, 2026.
The company will host a live conference call at 5:00 p.m. ET the same day. Participants can dial (877) 704-2848 or (201) 389-0893, and a live/archived webcast will be available at ir.edwards.com. Media and investor contact emails are provided for follow-up.
Edwards Lifesciences (NYSE: EW) will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast and same-day archived replay will be available on the company investor relations site.
Investors can access the webcast at http://ir.edwards.com/. Media and investor contact emails were provided for follow-up.
Edwards Lifesciences (NYSE: EW) said the U.S. District Court for the District of Columbia granted the U.S. Federal Trade Commission's motion for an injunction blocking Edwards' proposed acquisition of JenaValve Technology, and Edwards will not acquire JenaValve.
The company said it disagrees with the decision, reaffirmed its commitment to treating aortic regurgitation (AR), and will continue advancing the SOJOURN transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial. Edwards revised full-year 2026 adjusted EPS guidance to $2.90–$3.05 from $2.80–$2.95 and will provide further updates at its Fourth Quarter earnings call in February.
Edwards Lifesciences (NYSE: EW) announced FDA approval of the SAPIEN M3 transcatheter mitral valve replacement system on December 23, 2025, the first U.S. transseptal transcatheter therapy for mitral regurgitation.
The device is indicated for symptomatic moderate-to-severe or severe mitral regurgitation in patients deemed unsuitable for surgery or TEER, and for mitral valve dysfunction associated with mitral annular calcification. One-year ENCIRCLE pivotal trial data (299 patients) showed 95.7% MR ≤0/1+ and that the trial met all primary and secondary endpoints; the system received CE Mark in April 2025.
Edwards Lifesciences (NYSE: EW) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT, and Scott Ullem, chief financial officer, will also participate.
A live webcast will be available on the company investor relations site at http://ir.edwards.com/, with an archived version posted later the same day. The announcement notes contact emails for media and investor inquiries.